From the Department of Physiology, Kobe University School of Medicine,
Kobe, Japan.
Correspondence to T. Nishizaki, MD, PhD, Department of Physiology, Kobe University School of Medicine, 75-1 Kusunoki-cho, Chuo-ku, Kobe 650, Japan.
MethodsEndothelial cells were cultured from
bovine cerebral cortical arteries. Whole-cell patches were made to
cells, and glucose-evoked currents were recorded. Cells were
incubated with [3H]-2-DOG, and the uptake was determined
by a liquid scintillation counter.
ResultsGlucose and
Conclusions The results presented demonstrate that an
SGLT-like glucose transporter takes part in glucose uptake into brain
artery endothelial cells and that the uptake is
regulated by intracellular glucose concentrations; glucose-free insult
and the ensuing low cytosolic glucose enhance activity of the SGLT-like
glucose transporter. The SGLT-like glucose transporter in the brain
arterial endothelium thus may be important
in the maintenance of an adequate glucose concentration in the
arterial wall under conditions of stress, such as
hypoglycemia.
To address these questions, we monitored glucose-evoked
Na+ currents in cultured
endothelial cells from bovine cerebral cortical
arteries and assayed uptake of [3H]-2-DOG into
cells. We show here that low glucose enhances activity of the SGLT-like
glucose transporter and that this transporter may have a crucial role
in the maintenance of an adequate glucose concentration in the
arterial wall under conditions of stress, such as
hypoglycemia.
Immunohistochemistry
Electrophysiology
Assay of [3H]-2-DOG Uptake
Effect of SGLT-like Glucose Transporter Operation on Brain
Endothelial Cells
Regulation of SGLT-like Glucose TransporterOperated Currents by
Cytosolic Glucose
Cytochalasin B (1 µmol/L), a facilitative glucose transporter
(GLUT1 to GLUT5) inhibitor, markedly enhanced currents
induced by glucose (1 mmol/L), and 10 mmol/L glucose produced
currents in the presence of cyto B (Fig 3D
Uptake of [3H]-2-DOG Into Brain Endothelial
Cells
The SGLTs, which are identified in the small intestine and kidney,
continuously carry glucose into cells against its concentration
gradient as far as extracellular glucose is present; SGLT-operated
currents are not desensitized and enhanced in a glucose
concentrationdependent manner.14 In the
present study, glucose-induced currents were inhibited by the
selective SGLT inhibitor phlorizin, by the ATP uncoupler
DNP, by deletion of Na+ from extracellular
solution, or by
It is recognized that GLUT1 conveys glucose according to glucose
concentration gradient and is characterized by faster glucose transport
than the SGLTs. Interestingly, glucose-induced currents in brain
endothelial cells were potentiated in the presence of
cyto B, which suggests that cyto B produces the same condition as
glucose-free insult; cyto B predominantly blocks glucose entry via
GLUT1, and the eventual decrease in cytosolic glucose concentrations
enhances activity of the SGLT-like glucose transporter.
Uptake of 2-DOG into brain endothelial cells was
inhibited by over 95% by the facilitative glucose transporter
inhibitors phloretin and cyto B in cells without
glucose-free exposure, which indicates that GLUT1 is responsible for
glucose uptake into the endothelium under normal
conditions. On the other hand, the uptake was enhanced by pretreatment
with glucose-free media and the enhancement was inhibited by the SGLT
inhibitor, the energy metabolism
inhibitors, and the
Na+/K+-ATPase pump
inhibitor, and by deprivation of extracellular
Na+. This provides further evidence that
glucose-free insult followed by low cytosolic glucose enhances activity
of the SGLT-like glucose transporter, thus leading to an increase in
glucose uptake. It is presently unknown by what mechanism
glucose-free insult enhances activity of the SGLT-like glucose
transporter. A study15 has demonstrated that high
extracellular glucose inhibits insulin receptor kinase activity by
serine/threonine phosphorylation, suggesting that
glucose itself serves as a second messenger. The glucose signal may
stimulate the expression of the SGLT-glucose transporter or the
translocation of this transporter from cytosol to plasma membrane, or
it may directly activate this transporter. To address this
question, we are carrying out further experiments.
The GLUT1 and SGLT-like glucose transporter in the brain
endothelium, thus, appear to supply brain arteries with
glucose; the GLUT1 operates under normal conditions and, alternatively,
the SGLT-like glucose transporter under conditions of stress such as
hypoglycemia. The SGLT-like glucose transporter seems to be important
in the maintenance of an adequate glucose concentration in the
arterial wall. Another functional role of the SGLT-like
glucose transporter may be its involvement in transport of glucose
across the BBB. GLUT1 in brain capillaries is proposed to be the major
glucose transporter at the BBB.2 GLUT1 is
preferentially localized on the abluminal membranes of the
endothelium,3 and therefore
transport of glucose across the BBB cannot be explained by GLUT1 alone.
Considering that the BBB is composed of the
endothelium, with the tight junctions and foot
processes of the astrocytes, cultured brain endothelial
cells here may not reflect the function at the BBB. Cultured brain
endothelial cells, however, exhibited
In conclusion, the results presented here demonstrate that an
SGLT-like glucose transporter is involved in uptake into brain
endothelial cells as well as GLUT1 and that low glucose
enhances activity of the SGLT-like glucose transporter. The SGLT-like
glucose transporter seems to have a functional role in the
maintenance of an adequate glucose concentration in the
arterial wall under conditions of stress such as
hypoglycemia.
Received August 22, 1997;
revision received January 14, 1998;
accepted January 15, 1998.
2.
Pardridge WM, Boad RJ, Farrell CR. Brain-type glucose
transporter (GLUT-1) is selectively localized to the blood-brain
barrier. J Biol Chem. 1990;265:1803518040.
3.
Farrell CL, Pardridge WM. Blood-brain barrier glucose
transporter is asymmetrically distributed on brain capillary
endothelial luminal and abluminal membranes: an
electron microscopic immunogold study. Proc Natl Acad Sci
U S A. 1991;88:57795783.
4.
Nishizaki T, Kammesheidt A, Sumikawa K, Asada,
T, Okada Y. A sodium- and energy-dependent glucose transporter with
similarities to SGLT12 is expressed in bovine cortical vessels.
Neurosci Res. 1995;22:1322.[Medline]
[Order article via Infotrieve]
5.
Birnir B, Donald DDF, Wright EM. Voltage-clamp studies
of the Na+/glucose cotransporter cloned from
rabbit small intestine. Pflugers Arch. 1991;418:7985.[Medline]
[Order article via Infotrieve]
6.
Bell GI, Kayano T, Buse JB, Burant CF, Takeda J, Lin
D, Fukumoto H, Seino S. Molecular biology of mammalian glucose
transporters. Diabetes Care. 1990;13:198208.[Abstract]
7.
Thorens B. Facilitated glucose transporters in
epithelial cells. Annu Rev Physiol. 1993;55:591608.[Medline]
[Order article via Infotrieve]
8.
Hediger MA, Coady MJ, Ikeda TS, Wright EM. Expression
cloning and cDNA sequencing of the Na+/glucose
co-transporter. Nature. 1987;330:379381.[Medline]
[Order article via Infotrieve]
9.
Hediger MA, Turk E, Wright EM. Homology of the human
intestinal Na+/glucose and Escherichia coli
Na+/proline co-transporters. Proc Natl Acad
Sci U S A. 1989;86:57485752.
10.
Coady MJ, Pajor AM, Wright EM. Sequence homologies
among intestinal and renal Na+/glucose
co-transporters. Am J Physiol. 1990;259:C605610.
11.
Ohta T, Isselbacher KJ, Rhoads DB. Regulation of
glucose transporters in LLC-PK1 cells: effects of D-glucose and
monosaccharides. Mol Cell Biol. 1990;10:64916499.
12.
Morrison AI, Panayotova HM, Feigl G,
Scholermann B, Kinne RK. Sequence comparison of the
sodium-D-glucose cotransport systems in rabbit renal and
intestinal epithelia. Biochim Biophys Acta. 1991;1089:121123.[Medline]
[Order article via Infotrieve]
13.
Wells RG, Mohandas TK, Hediger MA.
Localization of the Na+/glucose co-transporter
gene SGLT2 to human chromosome 16 close to the centromere.
Genomics. 1993;17:787789.[Medline]
[Order article via Infotrieve]
14.
Wright EM. The intestinal
Na+/glucose cotransporter. Annu Rev
Physiol. 1993;55:575589.[Medline]
[Order article via Infotrieve]
15.
Pillay TS, Xiao S, Olefsky JM. Glucose
induced phosphorylation of the insulin
receptor-functional effects and characterization of
phosphorylation sites. J Clin Inves. 1996;97:613620.[Medline]
[Order article via Infotrieve]
16.
Orlowski M, Sessa G, Green JP.
Guest
Editors,
Anesthesiology/Critical Care Medicine,
Johns Hopkins Medical Institutions,
Baltimore, Maryland
The key finding is that SGLT activity is enhanced by low extracellular
glucose, which could serve as compensation for decreased glucose uptake
via GLUT1 under these conditions. In a series of well-designed
experiments, the authors demonstrate that SGLT activity is regulated by
cytosolic glucose. Addition of glucose to the pipette solution, which
represents the intracellular compartment, inhibited SGLT activity. A
dose-dependent inverse relationship was present between extracellular
glucose concentration and SGLT activity, an effect that is presumably
mediated by cytosolic glucose, because activation of SGLT by low
glucose is quickly desensitized. Regulation of SGLT by cytosolic
glucose is further supported by the observation that inhibiting
GLUT1-mediated glucose uptake (potentially depriving the cell of
glucose) leads to potentiation of SGLT activity. One major strength of
the study is its confirmation of electrophysiological findings by a
biochemical assay of glucose uptake with use of radiolabeled glucose.
The assay shows that depletion of cytosolic glucose by preincubation in
glucose-free solution enhances glucose uptake, and the increment is
abolished by inhibitors of SGLT or
Na+/K+-ATPase, which have little effect on
baseline uptake under normal glucose concentration.
The reader should be reminded that the main pathway for glucose uptake
into BAEC under normal glucose concentration is GLUT1-facilitated
diffusion. During normoglycemia, SGLT contributes very little to
glucose uptake. It must also be emphasized that the endothelial cells
of this study were isolated from large cerebral arteries, not from
brain capillaries that carry out the bulk of glucose transport across
the blood-brain barrier. The importance of SGLT in these cells remains
to be demonstrated. From a clinical perspective, it will be important
to compare these results in normal endothelial cells with those
obtained from diabetic or atherosclerotic vessels.
Received August 22, 1997;
revision received January 14, 1998;
accepted January 15, 1998.
© 1998 American Heart Association, Inc.
Original Contributions
Low Glucose Enhances Na+/Glucose Transport in Bovine Brain Artery Endothelial Cells
![]()
Abstract
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
Introduction
Background and
PurposeBrain arteries are structurally characterized by the
tight junctions of the endothelium and by no vasa
vasorum that feed arteries themselves. This raises the question of how
brain arteries are provided with glucose. A possible explanation is
that glucose uptake into arteries may be mediated by both GLUT1, a
facilitative glucose transporter, and a Na+/glucose
cotransporter (SGLT)-like glucose transporter. The functional role for
the SGLT-like glucose transporter, however, is unknown. In the
present study we investigated SGLT-like glucose
transporteroperated glucose uptake into brain arterial
endothelial cells by recording glucose-evoked
Na+ currents and monitoring uptake of
[3H]-2-deoxy-D-glucose
([3H]-2-DOG).
-methyl-D-glucoside (
MeDG),
a specific compound for the SGLTs, evoked Na+ currents in a
whole-cell voltage-clamp configuration, and the currents were enhanced
in cells with over 30 minutes' preincubation in glucose-free media.
Glucose-induced currents were inhibited by
MeDG, by the selective
SGLT inhibitor phlorizin, by dinitrophenol (DNP), an
inhibitor of energy metabolism, or by deletion
of Na+ from extracellular solution, which indicates that
glucose uptake into endothelial cells was mediated by a
Na+- and energy-dependent glucose transporter. Notably, the
currents were desensitized, reduced in a glucose
concentrationdependent manner, and markedly inhibited by either a
second application of glucose or the addition of glucose to the patch
electrode filling solution; they were potentiated, however, by
treatment with cytochalasin B, a GLUT1 to GLUT5 inhibitor.
Consistent with the results of patch-clamp recordings,
uptake of [3H]-2-DOG into endothelial
cells was enhanced by glucose-free insult, and the enhancement was
mediated by an SGLT-like glucose transporter.
Key Words: sodium-glucose transport system cerebral arteries endothelium glucose
![]()
Introduction
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
Introduction
Brain arteries
exhibit an unique structure distinct from body arteries; they are lined
with the tight junctions of the endothelium and have no
vasa vasorum to feed the arterial
wall.1 One therefore assumes that a carrier
protein for glucose, a glucose transporter, may provide brain arteries
with the major energy source glucose. Indeed, GLUT1, a facilitative
glucose transporter, is shown to be expressed in the rat brain
capillary endothelium2 3 and in
cultured endothelial cells from bovine cerebral
cortical arteries,4 thus supporting this
hypothesis. In addition, we earlier found that an SGLT-like glucose
transporter is expressed in cultured brain artery
endothelial cells as well as
GLUT1.4 This suggests the possibility that this
transporter may be also involved in glucose uptake into
endothelial cells. It is unknown, however, whether
glucose is actually taken up into endothelial cells
by this transporter, how this transporter is regulated, or what
functional role this transporter has.
![]()
Materials and Methods
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
Introduction
Cell Culture
Bovine brain endothelial cells were cultured as
described previously.4 Briefly,
endothelial cell sheets were mechanically isolated from
bovine cerebral cortical arteries 300 to 500 µm in diameter. The
explants were plated on collagen-coated dishes and grown in Dulbecco's
modified Eagle's medium with 20% fetal bovine serum, 1 ng/mL bovine
pituitary fibroblast growth factor, 50 IU/mL penicillin, and 50 mg/mL
streptomycin. The third-passage cells grown in 6-well, collagen-coated
dishes and in coverslips were used for assay of 2-DOG uptake and for
patch-clamp recording, respectively.
The brain arteries, endothelial cell sheets, and
cultured cells were fixed in 100% methanol, incubated in 0.3%
H2O2/methanol, and blocked
in 10% normal goat serum before incubation with anti-human factor
VIII/von Willebrand factor antibody (1:1000). The cells were
then stained with peroxidase-conjugated donkey anti-rabbit IgG and
3-amino-9-ethylcarbazole, followed by cell nucleus staining with
hematoxylin.
Cells were transferred to the recording chamber and
continuously superfused at room temperature (20°C to 22°C) with
glucose-free extracellular solution ([mmol/L] 145 NaCl, 5 KCl, 2.4
CaCl2, 10 HEPES, 0.3x10-3
tetrodotoxin, pH 7.4) after treatment with 10 mmol/L
glucose-containing or glucose-free extracellular solution at 37°C for
more than 30 minutes. For Na+-free extracellular
solution, 145 mmol/L NaCl was replaced with 145 mmol/L LiCl.
Whole-cell patches were made to the cells with use of patch electrode
filling solution consisted of (mmol/L) 150 KCl, 5 EGTA, 0.5 ATP, and 10
HEPES, pH 7.2. Membrane currents from whole-cell voltage-clamp were
recorded by an Axopatch-200A amplifier (Axon Instrument Inc). After
formation of whole-cell patches, series resistance compensation was
made up to
95%. Glucose was bath applied to cells during
recording. The currents were filtered at 5 kHz, stored on
magneto optical disk, and analyzed on a microcomputer with
pClamp software (version 6; Axon Instrument Inc).
The confluent cells with or without glucose-free exposure at
37°C were washed twice with glucose-free extracellular solution.
Subsequently, the cells were incubated for 10 minutes in extracellular
solution containing [3H]-2-DOG (specific
activity, 6.1 Ci/mL; Dupont) in the presence and absence of several
kinds of inhibitors. In some cases,
[3H]-2-DOG uptake was assayed in
Na+-free extracellular solution. After incubation
with [3H]-2-DOG, the cells were washed three
times with glucose/ Na+-free solution and then
lysed with 0.1% SDS. The levels of [3H]-2-DOG
uptake into endothelial cells were detected by a liquid
scintillation counter.
![]()
Results
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
Introduction
Cultured Endothelial Cells
The inner layer of the brain artery was positive against the
marker for endothelial cells, anti-factor VIII antibody
(Fig 1A
). The endothelial
cell sheet alone was isolated for cultures (Fig 1B
). Cultured cells
displayed uniform cobblestone appearance typical for
endothelial cells (Fig 1C
), and the cells were also
positive against anti-factor VIII antibody (Fig 1D
).

View larger version (98K):
[in a new window]
Figure 1. Cultured endothelial cells from
brain cortical arteries. The coronal section of the brain artery (A)
and the isolated endothelial cell sheet (B) were
stained with factor VIII antibody. Cultured endothelial
cells are shown in panel C; the cells were positive for factor VIII
staining (D).
Transport of glucose (D-isomer) mediated by the SGLTs can be
relatively estimated by monitoring Na+ currents
because Na+ is cotransported with glucose into
cells; otherwise, L-glucose evoked no current. We therefore
used D-glucose in this and further experiments. Application
of glucose (0.1 mmol/L) produced inward currents at a holding
potential of -60 mV in the whole-cell voltage-clamp configuration (Fig 2
). Notably, the currents were
potentiated after more than 30 minutes' pretreatment with glucose-free
extracellular solution (Fig 2
).
MeDG (0.1 mmol/L), a specific
compound for the SGLTs,5 also produced currents
to the same level as glucose (0.1 mmol/L) (Fig 2
). Currents evoked
by glucose (0.1 mmol/L) in cells with 1-hour glucose-free exposure
were inhibited by either the selective SGLT inhibitor
phlorizin (50 µmol/L) or the ATP uncoupler DNP (1 µmol/L)
(Fig 3A
). Glucose (0.1 mmol/L) never
produced currents in the presence of
MeDG (0.1 mmol/L) (Fig 3A
)
or in Na+-free extracellular solution (Fig 3B
).
Voltage pulses from -140 to +20 mV in 20-mV increments after
application of glucose (0.1 mmol/L) or
MeDG (0.1 mmol/L)
generated voltage-dependent inward currents that were inhibited by
phlorizin (50 µmol/L), although spontaneous currents were not
observed (Fig 4A
and 4B
). These results
indicate that a Na+/energy-dependent glucose
transporter (SGLT-like glucose transporter) was involved in glucose
uptake into brain endothelial cells and that the uptake
was enhanced by glucose-free insult.

View larger version (20K):
[in a new window]
Figure 2. Glucose- and
MeDG-evoked currents in brain
endothelial cells. Whole-cell patches were made to
cells with and without 1-hour exposure to glucose-free extracellular
solution, and glucose (0.1 mmol/L; n=7) or
MeDG (0.1
mmol/L; n=7) was applied to the cells. The holding potential was -60
mV. In this and following figures, inward currents correspond to
downward deflections.

View larger version (33K):
[in a new window]
Figure 3. SGLT-like glucose transporter in brain
endothelial cells. Whole-cell patches were made to
cells with 1-hour incubation in glucose-free extracellular solution. In
panel A, glucose (0.1 mmol/L) was applied to the cells in the
presence of phlorizin (50 µmol/L; n=7), DNP (1 µmol/L;
n=5), or
MeDG (0.1 mmol/L; n=5); in this case, glucose was
applied when
MeDG-induced currents reversed. B, glucose (0.1
mmol/L) was applied to a single cell in Na+-free
extracellular solution and, in turn, Na+-containing
extracellular solution (n=5). C, glucose (0.1 mmol/L) was
repetitively applied to a single cell at 15-minute intervals (n=7) or
applied to cells 5 minutes after patch formation with the patch
electrode filling solution containing 0.01 mmol/L glucose (n=7).
D, glucose (1 mmol/L) was applied to a single cell, and a second
application was carried out after treatment with 1 µmol/L cyto B
(n=7). In some cells, 10 mmol/L glucose was applied to cells in
the presence of cyto B (1 µmol/L; n=7). The holding potential
was -60 mV.

View larger version (35K):
[in a new window]
Figure 4. Glucose- and
MeDG-induced current/voltage
relations. Voltage pulses from -140 to 20 mV in 20-mV increments were
applied to cells with 1 hour of glucose-free exposure before and after
application of glucose (0.1 mmol/L; n=5) (A) or
MeDG (0.1
mmol/L; n=5) (B) in the presence and absence of phlorizin (50
µmol/L).
Currents induced by glucose (0.1 mmol/L) or
MeDG (0.1
mmol/L) were slowly desensitized, and a second application of glucose
elicited a still lesser response after a 15-minute washing (Fig 3C
). In
addition, when glucose (0.01 mmol/L) was added to patch electrode
filling solution, application of glucose (0.1 mmol/L) outside the
patch pipette evoked very small currents (Fig 3C
). Glucose-induced
currents reduced in a dose-dependent manner and >10 mmol/L
glucose produced no current (Fig 5
).
These results suggest that low cytosolic glucose enhanced glucose
uptake mediated by the SGLT-like glucose transporter; otherwise, high
cytosolic glucose inhibited the uptake.

View larger version (19K):
[in a new window]
Figure 5. Dose-response effect of glucose on the evoked
currents. Glucose was applied to cells with 1 hour of glucose-free
exposure at concentrations as indicated. The holding potential was -60
mV. Typical currents are illustrated in the upper panel, with results
summarized in the lower panel. Each point represents the
average percentage (±SD) of the current evoked by 0.1 mmol/L
glucose (n=5 to n=7).
) although no current was
evoked in the absence of cyto B (Fig 5
), further supporting the idea
that glucose uptake into endothelial cells mediated by
the SGLT-like glucose transporter is regulated by intracellular glucose
concentrations.
Uptake of 2-DOG into endothelial cells was
37.1±1.8 pmol/mg protein per 10 minutes in cells without glucose-free
exposure (Table 1
). The facilitative
glucose transporter inhibitors, such as phloretin (50
µmol/L) and cyto B (1 µmol/L), inhibited glucose uptake by
96% and 97%, respectively, whereas phlorizin (50 µmol/L), the
energy metabolism inhibitors DNP (1
µmol/L) and iodoacetate (1 µmol/L), the
Na+-K+/ATPase pump
inhibitor ouabain (100 µmol/L), or
deprivation of Na+ from extracellular
solution blocked the uptake by only 4% to 6% (Table 1
).
Consistent with the result of glucose-induced currents, 2-DOG
uptake was enhanced by 15.4 pmol/mg protein per 10 minutes in cells
with 1-hour incubation in glucose-free extracellular solution (
increase) (Table 1
). The enhancement was clearly inhibited by
phlorizin, DNP, iodoacetate, ouabain, and deprivation of
Na+, but, in contrast, it was not affected by
either phloretin or cyto B (Table 1
). This indicates that an
enhancement in 2-DOG uptake by glucose-free insult resulted from
activation of the SGLT-like glucose transporter.
View this table:
[in a new window]
Table 1. Uptake of [3H]-2-DOG Into Brain
Endothelial Cells
![]()
Discussion
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
Introduction
Plasma membranes are not permeable to a polar molecule glucose,
and glucose is therefore taken up into cells by glucose transporters.
Two families of glucose transporters are presently identified:
facilitative glucose transporters such as GLUT1 (erythrocyte/HepG2),
GLUT2 (liver), GLUT3 (brain), GLUT4 (muscle/fat), and GLUT5 (small
intestine),6 7 and SGLTs (small intestine/kidney)
such as SGLT1 and SGLT2.8 9 10 11 12 13 Extensive studies
have been carried out to understand the distribution of these glucose
transporters in a variety of tissues. Very little is known, however,
about glucose transporters in brain arteries. Brain arteries are likely
provided with glucose via glucose transporters, since they are not fed
by vasa vasorum and have a barrier that is formed by the tight
junctions of the endothelium. In an earlier
study,4 through use of immunohistochemical
analysis and Western immunoblot analysis,
we found that the GLUT1 and SGLT-like glucose transporter are expressed
in cultured endothelial cells from bovine brain
cerebral cortical arteries, which suggests that glucose uptake into the
endothelium is achieved by these transporters. The
present study provides further evidence for the expression of the
SGLT-like glucose transporter and makes clear its functional role in
brain arteries.
MeDG, a specific agent for the SGLTs.
MeDG
produced currents in a fashion that mimics the effect of glucose, which
indicates that an SGLT-like glucose transporter actually operates on
the endothelium of brain arteries. Notably, the
currents, inconsistent with those via the SGLTs in brush-border
membranes, were desensitized. More striking are the observations that
pretreatment with glucose-free media potentiated the currents and that
otherwise, repetitive applications of glucose, higher concentrations of
extracellular glucose, or addition of glucose to the patch electrode
filling solution markedly reduced the currents. These findings suggest
that the SGLT-like glucose transporter expressed in brain
endothelial cells has a characteristic distinct from
the SGLTs in brush-border membranes and is regulated by cytosolic
glucose concentrations.
-glutamyl
transpeptidase activity (205±7.9 nmol/mg protein per minute), a BBB
enzymatic marker16 whereas no activity was
obtained with cultured carotid artery endothelial
cells, which suggests that cultured brain endothelial
cells possess characteristics of the BBB. In addition, the findings
that glucose was transported across the arterial wall by
the SGLT-like glucose transporter in inverted cerebral cortical
arteries but not in noninverted ones and that glucose transport was not
observed in inverted carotid arteries4 indicate
that the SGLT-like glucose transporter is selectively expressed in
brain arteries and conveys glucose from the luminal membrane toward the
abluminal side. The SGLT-like glucose transporter may thus be
responsible for glucose uptake into the endothelium at
the BBB and the GLUT1 for glucose transport toward astrocytes just as
glucose is absorbed by the SGLT1/2 in the brush-border membranes and
exits the small intestine or renal tubules across the basolateral
membranes via GLUT2/5.14 To obtain further
evidence for this, we are currently testing uptake of glucose using
cocultures of astrocytes and endothelial cells.
![]()
Selected Abbreviations and Acronyms
BBB
=
blood-brain barrier
cyto B
=
cytochalasin B
DNP
=
dinitrophenol
2-DOG
=
2-deoxy-D-glucose
GLUT
=
facilitative glucose transporter
MeDG=
-methyl-D-glucoside
SGLT
=
Na+/glucose cotransporter
![]()
References
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
Introduction
1.
Edvinsson L, MacKenzie ET, McCulloch J.
Cerebral Blood Flow and Metabolism. New York,
NY: Raven Press Publishers; 1993:4056.
-glutamyl transpeptidase in brain capillaries: possible site of
a blood-brain barrier for amino acids. Science. 1974;184:6668.
Editorial Comment
![]()
Introduction
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
Introduction
Glucose is the source of metabolic energy in brain and requires
continuous transport from plasma to parenchyma. Two classes of glucose
carriers have been described in mammalian cell membranes: facilitative
glucose transporters, which transport glucose down its concentration
gradient, and Na+/glucose cotransporters, which couple the
downhill transport of Na+ with an uphill uptake of glucose.
However, it is unclear precisely which carriers are present in arterial
endothelial cells. GLUT1, a facilitative glucose transporter, and SGLT,
a type of Na+/glucose cotransporter, are known to be
present in cultured brain artery endothelial cells (BAEC). The present
study provides electrophysiological and biochemical evidence supporting
a role for SGLT in cultured BAEC under conditions of low glucose
concentration.
![]()
Selected Abbreviations and Acronyms
BBB
=
blood-brain barrier
cyto B
=
cytochalasin B
DNP
=
dinitrophenol
2-DOG
=
2-deoxy-D-glucose
GLUT
=
facilitative glucose transporter
MeDG=
-methyl-D-glucoside
SGLT
=
Na+/glucose cotransporter
This article has been cited by other articles:
![]() |
S. Vemula, K. E. Roder, T. Yang, G. J. Bhat, T. J. Thekkumkara, and T. J. Abbruscato A Functional Role for Sodium-Dependent Glucose Transport across the Blood-Brain Barrier during Oxygen Glucose Deprivation J. Pharmacol. Exp. Ther., February 1, 2009; 328(2): 487 - 495. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Y. Chan, J. A. Guggenheim, and C. H. To Is active glucose transport present in bovine ciliary body epithelium? Am J Physiol Cell Physiol, March 1, 2007; 292(3): C1087 - C1093. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Maschauer, O. Prante, M. Hoffmann, J. T. Deichen, and T. Kuwert Characterization of 18F-FDG Uptake in Human Endothelial Cells In Vitro J. Nucl. Med., March 1, 2004; 45(3): 455 - 460. [Abstract] [Full Text] |
||||
![]() |
H. Li, Y. Gu, Y. Zhang, M. J. Lucas, and Y. Wang High Glucose Levels Down-Regulate Glucose Transporter Expression That Correlates With Increased Oxidative Stress in Placental Trophoblast Cells IN Vitro Reproductive Sciences, February 1, 2004; 11(2): 75 - 81. [Abstract] [PDF] |
||||
![]() |
T. J. de Groot, M. Veyhl, C. Terwinghe, V. Vanden Bempt, P. Dupont, L. Mortelmans, A. M. Verbruggen, G. M. Bormans, and H. Koepsell Synthesis of 18F-Fluoroalkyl-{beta}-D-Glucosides and Their Evaluation as Tracers for Sodium-Dependent Glucose Transporters J. Nucl. Med., December 1, 2003; 44(12): 1973 - 1981. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. M. Bormans, G. Van Oosterwyck, T. J. de Groot, M. Veyhl, L. Mortelmans, A. M. Verbruggen, and H. Koepsell Synthesis and Biologic Evaluation of 11C-Methyl-D-Glucoside, a Tracer of the Sodium-Dependent Glucose Transporters J. Nucl. Med., July 1, 2003; 44(7): 1075 - 1081. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. E. Mann, D. L. Yudilevich, and L. Sobrevia Regulation of Amino Acid and Glucose Transporters in Endothelial and Smooth Muscle Cells Physiol Rev, January 1, 2003; 83(1): 183 - 252. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Aussedat, M. Dupire-Angel, R. Gifford, J. C. Klein, G. S. Wilson, and G. Reach Interstitial glucose concentration and glycemia: implications for continuous subcutaneous glucose monitoring Am J Physiol Endocrinol Metab, April 1, 2000; 278(4): E716 - E728. [Abstract] [Full Text] [PDF] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
Stroke Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1998 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |